This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Ensign Group Shares Are Attracting Investors Now
by Zacks Equity Research
ENSG stock is surging on revenue growth, acquisitions and raised 2025 earnings and sales guidance.
Here's Why Pediatrix Medical Shares Are Attracting Investors Now
by Zacks Equity Research
MD shares surge on strong earnings, rising revenues, cost cuts and a new $250M buyback plan.
PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
Phibro Animal Health posts strong Q4 earnings and revenues, fueled by Animal Health growth. Meanwhile, the gross margin contracts.
Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges
by Zacks Equity Research
ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.
MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up
by Zacks Equity Research
Medtronic tops on Q1 earnings and revenues, raises full-year EPS outlook, but shares dip on board changes.
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
by Zacks Equity Research
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
by Zacks Equity Research
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
EYE Stock Gains on Q2 Earnings and Revenue Beat, '25 View Up
by Zacks Equity Research
National Vision tops on Q2 earnings and revenues, boosts 2025 guidance after strong sales and margin expansion.
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
by Zacks Equity Research
Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.
Will GENEDX HOLDINGS (WGS) Gain on Rising Earnings Estimates?
by Zacks Equity Research
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
by Zacks Equity Research
BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up
by Zacks Equity Research
Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
by Zacks Equity Research
Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.
Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls
by Zacks Equity Research
TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
by Zacks Equity Research
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
by Zacks Equity Research
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
by Zacks Equity Research
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?
by Zacks Equity Research
Stryker's second-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs and tariffs are likely to have continued to hurt margins.
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +400.00% and +21.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?
by Zacks Equity Research
BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.
Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?
by Zacks Equity Research
GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.
Why GENEDX HOLDINGS (WGS) Could Beat Earnings Estimates Again
by Zacks Equity Research
GENEDX HOLDINGS (WGS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.